ENOV
EnovisANYSE / Health Care Equipment & Services
Last Price
At close
2026-07-21
Current thesis
The bull case is that investors eventually focus on the underlying operating picture rather than the goodwill write-down: FY2025 organic growth was 6%, Recon remained the stronger segment, and 2026 guidance implies another year of growth and EBITDA expansion if execution holds [#8-K-2026-02-26].
Posture
Constructive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta -0.4.
What can break
Execution miss versus 2026 organic growth, EBITDA, or EPS guidance could quickly reopen downside.
Momentum
68
Value
60
Sentiment
55
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $28.00 · Bull $36.00 · Bear $18.00
Data freshness
Prices
As of 2026-07-21
Fundamentals
As of 2026-07-21 • Vendor: Data Vendor v1
Scores
As of 2026-07-21 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-22 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-21
Investment thesis
As of 2026-07-21
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $40.73
Why
Momentum68 · Δ7d +33.6
Value60 · Δ7d -0.4
Sentiment55 · Δ7d -5.5
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Value · See fundamentals
Momentum
68
26% active weight
Current posture
7d trendImproving
Δ7d
+33.6
Δ21d
+56.6
Value
60
39% active weight
Current posture
7d trendFlat
Δ7d
-0.4
Δ21d
-1.6
Sentiment
55
34% active weight
Current posture
7d trendSoftening
Δ7d
-5.5
Δ21d
-26.2
Why this grade
Composite grade A. Momentum 67.6 / Value 59.5 / Sentiment 55.2
Fundamentals (TTM)As of 2026-07-21
Fundamentals (TTM)
As of 2026-07-21
Market Cap
$1.56B
Beta
1.29
Shares Out
57.56M
P/E (TTM) · Derived
-1.3
P/S (TTM)
0.69
P/FCF (TTM)
67.85
Rev YoY
+5.4%
EPS YoY
-84.5%
Gross Margin
+52.6%
Op Margin
-57.7%
Net Debt
$1.34B
Current Ratio
2.04
As of 2026-07-21 • Updated nightlySource: Internal modelMethodology